Eli Lilly
Triumph-1, Triumph-2, Triumph-3
Over the last year or so, Eli Lilly has seized control of the fast-evolving obesity drug market and, in the process, become by far the world’s most valuable drugmaker. Lilly’s top treatment is now the world’s best selling drug, and the company soon stands to launch one of the first oral “incretin” medicines for weight loss. .
Lilly could further cement its leading position this year, when a series of studies on a drug called retatrutide produce results.
The drug targets a metabolic pathway called glucagon in addition to the GLP-1 and GIP that Lilly’s fast-selling Zepbound does — a triple-acting effect that could enhance weight loss. Zepbound set a high bar by helping people with obesity lose up to 21% of their body weight over more than a year. But in a Phase 3 trial in a type of knee pain last year, retatrutide delivered even more drastic results, spurring average weight loss of as much as nearly 29% and, in some cases, more than 35%.
